BBIO News and Press, BridgeBio Pharma Inc. From 03/04/24

- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiered structure beginning in the low-thirties percent, designed to provide Br...

2024-02-29 06:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-15 09:12:07 ET More on Alnylam Pharmaceuticals Alnylam's Huge Opportunity Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Alnylam Pharmaceuticals Q4 2023 Earnings Preview Investors growing more bullish on SMID cap biotech stocks S...

2024-02-07 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-07 10:37:54 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Pharma granted FDA review f...

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront payment of USD 100 million with royalties up to the high-twenties percent, with additional milestone-based payments - Infigr...

2024-02-05 07:56:15 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Pharma inks royalty deal fo...

- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application - Marketing Authorization Application accepted by the European Medicines Agency (EMA) with additional global r...

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported over the 30 month acoramidis treatment period - Acoramidis was w...

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics PR Newswire SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partner...